Although the JAK1/2 inhibitor suppressed several hallmarks of MPN, including splenomegaly, or reduction of WBC counts, JAK2V617F expressing cells persisted in spleens and bone marrow. This evidence concerns the gene JAK1 and myeloproliferative disorder.